Table 3.
Correlation between Bmi-1 expression and the clinicopathologic features of breast cancer
| Bmi-1 Expression | Total | χ2 | P-value | ||
|---|---|---|---|---|---|
| Low | High | ||||
| N (%) | N (%) | N (%) | |||
| Age | 0.36 | 0.551 | |||
| ≤45 year | 26 (26.3) | 73 (73.7) | 99 (41.2) | ||
| >45 year | 42 (29.8) | 99 (70.2) | 141 (58.8) | ||
| T Classification | 30.92 | <0.001 | |||
| T1 | 26 (57.8) | 19 (42.2) | 45 (17.9) | ||
| T2 | 35 (25.9) | 100 (74.1) | 135 (53.6) | ||
| T3 | 9 (17.3) | 43 (82.7) | 52 (20.6) | ||
| T4 | 0 (0.0) | 20 (100.0) | 20 (7.9) | ||
| N Classification | 46.45 | <0.001 | |||
| N0 | 48 (53.3) | 42 (46.7) | 90 (35.7) | ||
| N1 | 20 (15.2) | 112 (84.8) | 132 (52.4) | ||
| N2 | 0 (0.0) | 22 (100.0) | 22 (8.7) | ||
| N3 | 2 (25.0) | 6 (75.0) | 8 (3.2) | ||
| M Classification | 14.87 | <0.001 | |||
| M0 | 68 (32.9) | 139 (67.1) | 207 (82.7) | ||
| M1 | 2 (4.4) | 43 (95.6) | 45 (17.9) | ||
| Clinical Stage | 82.06 | <0.001 | |||
| I | 16 (69.6) | 7 (30.4) | 23 (9.1) | ||
| II | 48 (51.1) | 46 (48.9) | 94 (37.3) | ||
| III | 4 (4.4) | 86 (95.6) | 90 (35.7) | ||
| IV | 2 (4.4) | 43 (95.6) | 45 (17.9) | ||
| ER Presence | 1.53 | 0.217 | |||
| Negative | 38 (31.4) | 83 (68.6) | 121 (48.0) | ||
| Positive | 32 (24.4) | 99 (75.6) | 131 (52.0) | ||
| PR Presence | 0.04 | 0.837 | |||
| Negative | 29 (27.1) | 78 (72.9) | 107 (42.5) | ||
| Positive | 41 (28.3) | 104 (71.7) | 145 (57.5) | ||
| HER-2 Presence | 0.71 | 0.400 | |||
| Negative | 17 (33.3) | 34 (66.7) | 51 (32.1) | ||
| Positive | 29 (26.9) | 79 (73.1) | 108 (67.9) | ||
Four categories of the percentage of positive cells: 1: ≤5%; 2: 6%-35%; 3: 36%-70%; 4: ≥71% (40X).
Four categories of the staining intensity: 1: negative; 2: weak; 3: moderate; 4: strong.
Final score = score of percentage of positive cells × score of staining intensity. If the final score was >4, Bmi-1 expression was considered high, otherwise, Bmi-1 expression was considered low.